Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
about
Biomedical and clinical promises of human pluripotent stem cells for neurological disordersModeling Parkinson's disease in the common marmoset (Callithrix jacchus): overview of models, methods, and animal careResearch Findings on Overactive BladderPioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammationMultimodal MRI Evaluation of the MitoPark Mouse Model of Parkinson's DiseaseCell-permeable parkin proteins suppress Parkinson disease-associated phenotypes in cultured cells and animalsComparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's DiseaseUnprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's diseaseAn Efficient and Versatile System for Visualization and Genetic Modification of Dopaminergic Neurons in Transgenic MiceSpontaneously Hypertensive Rats (SHR) Are Resistant to a Reserpine-Induced Progressive Model of Parkinson's Disease: Differences in Motor Behavior, Tyrosine Hydroxylase and α-Synuclein ExpressionDopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease.Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse.Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synucleinBrain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.Normalization of Reverse Transcription Quantitative PCR Data During Ageing in Distinct Cerebral Structures.Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates.Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulationNon-motor Parkinson's: integral to motor Parkinson's, yet often neglected.A mouse line for inducible and reversible silencing of specific neuronsTargeting NOX enzymes in the central nervous system: therapeutic opportunities.A new quantitative rating scale for dyskinesia in nonhuman primates.8-Benzyltetrahydropyrazino[2,1-f]purinediones: water-soluble tricyclic xanthine derivatives as multitarget drugs for neurodegenerative diseases.1-Methyl-4-phenylpyridinium stereotactic infusion completely and specifically ablated the nigrostriatal dopaminergic pathway in rhesus macaqueIn vivo imaging of CREB phosphorylation in awake-mouse brain.The temporary and accumulated effects of transcranial direct current stimulation for the treatment of advanced Parkinson's disease monkeysSusceptibility to a parkinsonian toxin varies during primate developmentNeuroprotective effect of nerolidol against neuroinflammation and oxidative stress induced by rotenone.Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's diseaseCombination of acamprosate and baclofen as a promising therapeutic approach for Parkinson's disease.Supramolecular Inhibition of Neurodegeneration by a Synthetic ReceptorImpact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's diseaseCell based therapy in ParkinsonismFunctional Rescue of Dopaminergic Neuron Loss in Parkinson's Disease Mice After Transplantation of Hematopoietic Stem and Progenitor Cells.Behavioral effects of bidirectional modulators of brain monoamines reserpine and d-amphetamine in zebrafish.Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models.Modeling Parkinson's disease in monkeys for translational studies, a critical analysis.Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.Oxidative stress in genetic mouse models of Parkinson's disease.
P2860
Q21284798-0BD57A82-FA00-43B9-86DB-46FC4162C22BQ26772285-04710268-EAC8-42B6-92DD-43214BD364DFQ26801459-BBAE1AA1-7069-440E-876C-A31972D0FD20Q27301100-351BCF5C-B758-4C1F-B1FD-EB12F122D489Q27316725-2CC4286C-D1F1-4E24-8BB9-2B6DF55B02E4Q27318797-18184FA3-D1CA-412D-BD85-5B0CAED369B0Q27320553-7E14BF7C-323D-48F6-AAB5-2C0D4A136761Q28542729-DDD2504D-E3A8-414E-9EE9-429A98304E34Q28547378-4945B65F-8234-424D-94A5-FDDAA86D0727Q30359033-ECD38DA3-14D4-4A38-A61B-7FA2F14ED31AQ30372768-C1919EF2-291B-4CA6-A49E-F729C03AF22AQ30512976-E369BEE0-5C45-4329-97F8-D45C8FA503BFQ30541996-8B15A8D8-9E0E-4D38-B889-A11AFA3FC551Q30633819-C356C5B4-6B70-4893-B3F1-8409851E53FCQ30833645-84C87890-6452-4B4C-9026-52F62EE6814AQ30890022-C435868B-A46F-4E40-9BE5-DEB484725C71Q34112026-2EDBA745-BA3F-4FEC-8434-3D4FD24266C0Q34195302-6578243F-F2A1-4B60-925C-60E51D8346C6Q34223052-04B94F94-640D-43FE-8BA3-D1ADBCDD62ABQ34239492-C42E46BF-96C9-40A9-9F42-FA035B86B774Q34253305-AD76CC12-9D7B-40CF-9C55-401C2EC4B39AQ34285497-DE9F987B-64FB-4B39-B78F-C8615728CA30Q34771498-220ADDAE-4A81-4AEA-B660-7C197A7062C1Q35166780-B4D496C9-F3BC-430E-B395-702BF0686955Q35641515-B5ED8513-C887-41C0-AC22-E0D37A1D5F70Q35686413-0B4D69BB-2481-4905-874C-D501EE216D07Q35898196-FFDF4378-4BD6-436A-B4F4-FECD15EE199FQ35907253-ADD8568B-BE70-4C44-A62F-FECDF19A3472Q36109494-66EA00E2-1E3A-4278-A7D1-7BEF92B47DB4Q36252786-54D98213-5F73-46EF-B6CA-7BBBDE438B34Q36254618-B7121012-87B1-4939-9F81-05B8B3A92C9EQ36367293-9F86307C-BF47-4A34-9C3D-CF9ED5F8943FQ36462680-55B7C9B9-29D0-4FB6-85EA-9465F3D5F02AQ36908657-F24BEBB7-85F4-40BE-8B91-1E420A7CDEC7Q37034654-11E9A227-1600-4E30-94F2-791AA6AA2B00Q37398726-BA8ACD77-2C69-4E17-8071-2FFD9B052592Q37644437-9B63B155-374C-4654-8FA1-0A90853E1D79Q37656643-6D92C249-FDF5-4642-800D-7F8C75033326Q38021940-7939E42C-DC75-4D52-AEB2-FC5CD74235EEQ38029327-8DACA1BB-F117-41FB-A648-4D8E30BD92B0
P2860
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Animal models of Parkinson's d ...... s to the cause of the disease.
@ast
Animal models of Parkinson's d ...... s to the cause of the disease.
@en
type
label
Animal models of Parkinson's d ...... s to the cause of the disease.
@ast
Animal models of Parkinson's d ...... s to the cause of the disease.
@en
prefLabel
Animal models of Parkinson's d ...... s to the cause of the disease.
@ast
Animal models of Parkinson's d ...... s to the cause of the disease.
@en
P2860
P1476
Animal models of Parkinson's d ...... es to the cause of the disease
@en
P2093
Peter Jenner
P2860
P304
P356
10.1111/J.1476-5381.2011.01426.X
P407
P50
P577
2011-10-01T00:00:00Z